Ventripoint starts congenital heart defect mktg program

Executive Summary

• Ventripoint Diagnostics Ltd. has launched a targeted marketing program focused on the diagnosis and monitoring of congenital heart defects (CHD), aiming to solidify its leadership position in this clinical area.
• The initiative centers on the company's flagship VMS+ system, which provides MRI-comparable volumetric and functional cardiac measurements using standard echocardiography, addressing accessibility barriers for CHD patients.
• The program is designed to serve as a foundation for expansion into other high-growth segments, including cardio-oncology, pulmonary hypertension, heart failure, and valvular heart disease.

Key Details

• Core Technology: The marketing program highlights the VMS+ system, which delivers MRI-comparable volumetric and functional cardiac measurements using standard echocardiography, eliminating patient and workflow barriers associated with cardiac MRI.
• Strategic Focus: The immediate focus is on Congenital Heart Defects (CHD), with the long-term goal of leveraging this foothold to expand into cardio-oncology, pulmonary hypertension, heart failure, and valvular heart disease.
• Program Components:
  • Industry Partnerships: Continued collaboration with partners such as ASCEND Cardiovascular to cross-market and promote AI-enhanced echocardiography solutions.
  • Clinical Education: Building relationships with pediatric and adult congenital cardiology centers to demonstrate workflow integration and patient benefits.
  • Patient Advocacy: Collaboration with the Ollie Hinkel Heart Foundation and development of relationships with other CHD advocacy organizations to increase awareness.
  • KOL Partnerships: Working with clinical advisers to publish CHD case studies and peer-reviewed data to reinforce VMS+ as the standard of care for functional cardiac assessment without MRI.
• Market Opportunity: CEO Hugh MacNaught notes that CHD represents a challenging and underserved population, providing a platform to prove the value proposition before expanding into markets with exponentially larger addressable markets.
• Regulatory Status: VMS+ is versatile and compatible with all ultrasound systems from any vendor, supported by regulatory market approvals in the United States, Europe, and Canada.
• Future Communications: Ventripoint will provide updates on program milestones and commercial progress in upcoming quarterly communications.

Notable Quotes

• "CHD patients face a lifetime of imaging, yet many cannot access MRI due to cost, availability or clinical limitations. Our VMS+ technology solves that challenge by enabling fast, accurate and comfortable assessments using widely available ultrasound equipment. By leading in CHD, we are also building the clinical credibility and installed base needed to accelerate adoption in other high-value segments." — Hugh MacNaught, President and CEO
• "Each of these markets represents a significant growth opportunity, but CHD offers a unique platform for proving our value proposition in the most challenging and underserved patient population. From there, our addressable market expands exponentially." — Hugh MacNaught, President and CEO